

Supplementary table 2. Baseline characteristics of patients according to continue or discontinued of RAS inhibitor during index admission

Variable	Continue RAS inhibitor	Discontinue RAS inhibitor	P value
Age, years	75.8 ± 6.7	76.3 ± 6.5	0.481
Men, n (%)	400 (55.9)	70 (53.4)	0.633
BMI, kg/m ²	23.1 ± 3.5	22.9 ± 3.3	0.562
Medical history			
Previous heart failure, n (%)	512 (71.6)	92 (70.2)	0.753
Hypertension, n (%)	543 (75.9)	102 (77.9)	0.738
Diabetes, n (%)	343 (48.0)	70 (53.4)	0.256
Atrial fibrillation, n (%)	235 (32.9)	34 (26.0)	0.127
COPD, n (%)	95 (13.3)	19 (14.5)	0.678
Myocardial infarction, n (%)	220 (30.8)	52 (39.7)	0.053
Medication on discharge			
Beta-blocker, n (%)	380 (53.1)	58 (44.3)	0.071
MRA, n (%)	348 (48.7)	49 (37.4)	0.022
Loop diuretics, n (%)	159 (22.2)	44 (33.6)	0.007
Digoxin, n (%)	483 (67.6)	99 (75.6)	0.081
Systolic BP on admission, mm Hg	134.7 ± 28.6	127.1 ± 31.3	0.006
Diastolic BP on admission, mm Hg	79.8 ± 16.8	73.1 ± 17.3	<0.001
Heart rate on admission, beats/min	91.4 ± 24.6	96.9 ± 22.5	0.018
NYHA functional class III or IV on admission	623 (87.1%)	117 (89.3)	0.567

Laboratory data on admission

eGFR, ml/min/1.73m ²	53.3 ± 23.6	39.5 ± 20.8	<0.001
Sodium, mEq/L	137.6 ± 4.9	136.8 ± 4.5	0.062
Potassium, mEq/L	4.4 ± 0.7	4.7 ± 0.8	0.001
BNP, pg/mL	1670.8 ± 1502.2	1920.8 ± 2017.2	0.355
NT-pro-BNP, pg/mL	10966.0 ± 10806.0	14939.1 ± 12170.9	0.007
LVEF, %	28.6 ± 7.5	28.6 ± 7.4	0.929

BMI, body mass index; COPD, chronic obstructive pulmonary disease; RAS, renin angiotensin system; MRA, mineralocorticoid receptor antagonist; BP, blood pressure; GFR, glomerular filtration rate; BNP, brain natriuretic peptide; LVEF, left ventricular ejection fraction